Olatoyosi Odenike to Benzamides
This is a "connection" page, showing publications Olatoyosi Odenike has written about Benzamides.
Connection Strength
1.079
-
The Next Generation of JAK Inhibitors: an Update on Fedratinib, Momelotonib, and Pacritinib. Curr Hematol Malig Rep. 2020 12; 15(6):409-418.
Score: 0.688
-
Patients with myeloid malignancies bearing PDGFRB fusion genes achieve durable long-term remissions with imatinib. Blood. 2014 Jun 05; 123(23):3574-7.
Score: 0.108
-
A 32-year-old man with persistent cough, shortness of breath, eosinophilic pneumonia, and peripheral blood eosinophilia. Myeloid neoplasm associated with eosinophilia and platelet-derived growth factor receptor-alpha rearrangement. Chest. 2012 Dec; 142(6):1680-1683.
Score: 0.099
-
Phase I/II multicenter study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of AZD4877 in patients with refractory acute myeloid leukemia. Invest New Drugs. 2012 Jun; 30(3):1107-15.
Score: 0.088
-
Conventional and new treatment options for myelofibrosis with myeloid metaplasia. Semin Oncol. 2005 Aug; 32(4):422-31.
Score: 0.059
-
Feasibility of administering oblimersen (G3139; Genasense) with imatinib mesylate in patients with imatinib resistant chronic myeloid leukemia--Cancer and leukemia group B study 10107. Leuk Lymphoma. 2008 Jul; 49(7):1274-8.
Score: 0.018
-
Successful autologous stem cell collection in patients with chronic myeloid leukemia in complete cytogenetic response, with quantitative measurement of BCR-ABL expression in blood, marrow, and apheresis products. Leuk Lymphoma. 2008 Mar; 49(3):531-7.
Score: 0.018